Balancing Near-Term Headwinds and Strategic Transition: Why a Hold Rating Remains Warranted

TD Cowen analyst Yaron Werber maintained a Hold rating on BioNTech SE today and set a price target of $94.00.

Yaron Werber has given his Hold rating due to a combination of factors, balancing weaker near‑term fundamentals with improving strategic positioning. He views the lower FY26 revenue outlook as largely driven by the expected decline in COVID‑19 vaccine sales, partially offset by disciplined operating expense guidance that signals more cautious, prioritized investment.

At the same time, he sees the planned transition of the founding CEO and CMO and the move toward a more commercially oriented leadership team as an important, but still unproven, catalyst for a future turnaround. Given the history of an overextended and slow‑moving pipeline, execution missteps, and shaken investor confidence, he believes that upcoming late‑stage data and initial oncology launches could improve the story, but that it will take time and evidence before a more constructive rating is warranted.